Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement, impacting overall financial performance [1]. Financial Performance - Total revenue for the period was 13.273 billion RMB, representing a year-on-year decrease of 18.5% [1]. - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% compared to the previous year [1]. - Basic earnings per share were 22.29 cents [1]. Dividend Announcement - The company proposed an interim dividend of 0.14 HKD per share, down from 0.16 HKD in the same period last year [1]. Gross Margin Analysis - The gross margin for the period decreased by 6.0 percentage points to 65.6%, primarily due to a reduced revenue contribution from the prescription drug business [1].

Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement [1] Financial Performance - Total revenue for the period was 13.273 billion RMB, representing a year-on-year decrease of 18.5% [1] - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year [1] - Basic earnings per share were 0.2229 RMB [1] - The company proposed an interim dividend of 0.14 HKD per share, compared to 0.16 HKD in the same period last year [1] Margin Analysis - Gross profit margin decreased by 6.0 percentage points to 65.6% compared to the same period last year [1] - The decline in gross margin was mainly attributed to a reduced proportion of revenue from the prescription drug business [1]

Group 1 - The company reported total revenue of approximately 13.273 billion RMB for the six months ending June 30, 2025, representing a year-on-year decrease of 18.5% [1] - The reported profit attributable to shareholders was approximately 2.548 billion RMB, a decrease of 15.6% year-on-year, with basic earnings per share at 0.2229 RMB [1] - The decline in revenue was primarily due to the inclusion of the products Dumex® and Tsinghua® in centralized procurement [1] Group 2 - The gross profit margin decreased by 6.0 percentage points to 65.6%, mainly due to the reduced revenue share from prescription drugs [1] - Research and development expenses increased by 5.5% year-on-year to 2.683 billion RMB, accounting for 26.2% of prescription drug revenue [1] - The company has nearly 90 products in various stages of clinical trials, with 12 submitted for market approval and over 30 key products in the registration clinical stage [1] Group 3 - The company has over 200 innovative drugs and formulations in development, including more than 90 macromolecules, 60 small molecules, and 50 new formulations [1] - There are currently over 160 clinical trials ongoing, with nearly 60 in Phase III [1] - The company expects to submit over 50 new drugs or new indications for approval by the end of 2028 [1] Group 4 - Year-to-date, the company has received approval for 3 innovative products, acceptance for 5 product applications, breakthrough therapy designations for 4 products, and 28 clinical trial approvals [2] - The company also obtained 7 registration approvals for generic drugs and 9 clinical trial approvals for innovative drugs in North America, along with 1 fast track designation [2]

Core Viewpoint - The company, 石药集团 (Stone Group), announced a mid-term dividend of HKD 0.14 per share, to be distributed on November 18, 2025 [1] Company Summary - 石药集团 will distribute a mid-term dividend of HKD 0.14 per share [1]

Core Viewpoint - The company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of key products in centralized procurement, but it remains optimistic about future growth through innovation and international collaboration [1][2][3]. Financial Performance - Total revenue for the first half of 2025 was 13.273 billion RMB, a decrease of 18.5% year-on-year - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year - Basic earnings per share were 0.2229 RMB, with an interim dividend proposed at 0.14 HKD per share [1]. Research and Development - R&D expenses increased by 5.5% year-on-year to 2.683 billion RMB, accounting for 26.2% of the revenue from the pharmaceutical business - The company has nearly 90 products in various stages of clinical trials, with 12 submitted for market approval and over 30 key products in the registration clinical phase [1][4]. Strategic Initiatives - The company is focusing on a "dual-driven" strategy of "innovation + internationalization," enhancing partnerships with global pharmaceutical firms through diverse models such as licensing and collaborative R&D - In the first half of 2025, licensing revenue reached 1.075 billion RMB, indicating strong recognition of the company's innovative pipeline in the international pharmaceutical industry [2][3]. Global Expansion - The company is advancing its global strategy by establishing a comprehensive pharmaceutical value ecosystem and conducting multiple multi-center clinical trials in Europe and the U.S. - It has completed four licensing projects this year, with a cumulative contract amount of 9.71 billion USD, and has entered a strategic R&D collaboration with AstraZeneca [3][4]. Innovation Pipeline - The company has been recognized as one of the top 25 pharmaceutical companies globally by Citeline for three consecutive years, ranking 19th this year, an improvement of five places from the previous year - It has over 200 innovative drugs and formulations in development, with more than 160 clinical trials ongoing, including nearly 60 in Phase III [4].

Core Viewpoint - The company, CSPC Pharmaceutical Group (stock code: 01093), announced a mid-term dividend of HKD 0.14 per share, which will be distributed on November 18, 2025 [1] Company Summary - CSPC Pharmaceutical Group will distribute a mid-term dividend of HKD 0.14 per share [1]

Group 1: Financial Performance - The company reported total revenue of 13.273 billion RMB, a year-on-year decrease of 18.5% [1] - Profit attributable to shareholders was 2.548 billion RMB, down 15.64% year-on-year, with basic earnings per share at 22.29 cents [1] - The gross profit margin decreased by 6.0 percentage points to 65.6%, primarily due to a reduction in the revenue share from the prescription drug business [1] Group 2: Research and Development - R&D expenses increased by 5.5% year-on-year to 2.683 billion RMB, accounting for 26.2% of prescription drug revenue [1] - The company has nearly 90 products in various stages of clinical trials, with 12 submitted for market approval and over 30 key products in the registration clinical phase [1] - The company focuses on high-demand treatment areas such as breast cancer and lung cancer, accelerating the commercialization of core products [2] Group 3: Strategic Initiatives - The company is implementing a "dual-driven" strategy of "innovation + internationalization," enhancing cooperation with global innovative pharmaceutical companies [2] - Authorization revenue reached 1.075 billion RMB in the first half of 2025, providing new growth momentum for the prescription drug business [2] - The company has completed four external authorization projects with a cumulative contract amount of 9.71 billion USD [3] Group 4: Global Expansion and Recognition - The company has been recognized as a "national-level innovative enterprise" and has established key national laboratories [4] - It ranks 19th in the global TOP25 pipeline scale pharmaceutical companies, improving its position by 5 places compared to the previous year [4] - The company is expected to submit over 50 new drugs or new indications for approval by the end of 2028 [4]

Group 1 - The core viewpoint of the article highlights that Shijiazhuang Pharmaceutical Group (01093.HK) reported a decline in its mid-year performance for 2025, with revenue and net profit both decreasing significantly [1] Group 2 - The company reported a revenue of 13.27 billion RMB for the first half of 2025, representing a year-on-year decrease of 18.5% [1] - The net profit for the same period was 2.55 billion RMB, which is a year-on-year decrease of 15.6% [1]

Group 1 - The core viewpoint of the article is that the company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement [1] - The company's total revenue for the first half of 2025 was RMB 13.273 billion, representing an 18.5% year-on-year decrease [1] - The reported profit attributable to shareholders was RMB 2.548 billion, a decrease of 15.6% compared to the previous year [1] Group 2 - The basic earnings per share were RMB 0.2229, and the board declared an interim dividend of HKD 0.14 per share for the 2025 fiscal year [1] - The revenue from the prescription drug business was RMB 10.248 billion, down 24.4% year-on-year [1] - Revenue from raw material products increased by 11.9% to RMB 2.075 billion, while revenue from functional foods and other businesses grew by 8.0% to RMB 0.951 billion [1]

| 其他信息 | | --- | | 其他信息 不適用 | | 發行人董事 | | 於 本 公 告 日 期 ，董 事 會 包 括 執 行 董 事 蔡 東 晨 先 生 、張 翠 龍 先 生 、王 振 國 先 生 、潘 衛 東 先生、王懷玉先生、李春雷 博士、姚兵博士、蔡鑫先生及陳衛平先生；及獨立非執行董事王波先生、CHEN Chuan先生、王宏廣教授、歐振國先生、羅卓堅先 | | 生及李泉女士。 | 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 石藥集團有限公司 | | 股份代號 | 01093 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年六月三十日止六個月之中期股息 | | ...